Cargando…

Oxidation resistance 1 is a novel senolytic target

The selective depletion of senescent cells (SCs) by small molecules, termed senolytic agents, is a promising therapeutic approach for treating age‐related diseases and chemotherapy‐ and radiotherapy‐induced side effects. Piperlongumine (PL) was recently identified as a novel senolytic agent. However...

Descripción completa

Detalles Bibliográficos
Autores principales:	Zhang, Xin, Zhang, Suping, Liu, Xingui, Wang, Yingying, Chang, Jianhui, Zhang, Xuan, Mackintosh, Samuel G., Tackett, Alan J., He, Yonghan, Lv, Dongwen, Laberge, Remi‐Martin, Campisi, Judith, Wang, Jianrong, Zheng, Guangrong, Zhou, Daohong
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2018
Materias:	Original Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6052462/ https://www.ncbi.nlm.nih.gov/pubmed/29766639 http://dx.doi.org/10.1111/acel.12780

Ejemplares similares

Discovery of piperlongumine as a potential novel lead for the development of senolytic agents
por: Wang, Yingying, et al.
Publicado: (2016)

Using proteolysis-targeting chimera technology to reduce navitoclax platelet toxicity and improve its senolytic activity
por: He, Yonghan, et al.
Publicado: (2020)

The curcumin analog EF24 is a novel senolytic agent
por: Li, Wen, et al.
Publicado: (2019)

Inhibition of USP7 activity selectively eliminates senescent cells in part via restoration of p53 activity
por: He, Yonghan, et al.
Publicado: (2020)

Assays and technologies for developing proteolysis targeting chimera degraders
por: Liu, Xingui, et al.
Publicado: (2020)

Senescence and Senolytics: State of the Art on Cellular Senescence, Senolytics, and Healthspan
por: Campisi, Judith
Publicado: (2020)

Proteolysis targeting chimeras (PROTACs) are emerging therapeutics for hematologic malignancies
por: He, Yonghan, et al.
Publicado: (2020)

Why Senescent Cells Are Resistant to Apoptosis: An Insight for Senolytic Development
por: Hu, Li, et al.
Publicado: (2022)

PROTACs are effective in addressing the platelet toxicity associated with BCL-X(L) inhibitors
por: Zhang, Peiyi, et al.
Publicado: (2020)

DT2216—a Bcl-xL-specific degrader is highly active against Bcl-xL-dependent T cell lymphomas
por: He, Yonghan, et al.
Publicado: (2020)

PROteolysis TArgeting Chimeras (PROTACs) as emerging anticancer therapeutics
por: Khan, Sajid, et al.
Publicado: (2020)

Paradoxes of senolytics
por: Blagosklonny, Mikhail V.
Publicado: (2018)

Lamin B1 loss is a senescence-associated biomarker
por: Freund, Adam, et al.
Publicado: (2012)

p53: Pro-aging or pro-longevity?
por: de Keizer*, Peter L.J., et al.
Publicado: (2010)

A selective BCL-X(L) PROTAC degrader achieves safe and potent antitumor activity
por: Khan, Sajid, et al.
Publicado: (2019)

Senolytics in a Model of Alzheimer's Disease
por: Wang, Ellen, et al.
Publicado: (2021)

Targeting anxiety and senescence with senolytics
por: Raffaele, Marco, et al.
Publicado: (2022)

Senolytics in the treatment of diabetic retinopathy
por: Hassan, Jannah Waled, et al.
Publicado: (2022)

Strategies for senolytic drug discovery
por: Power, Helen, et al.
Publicado: (2023)

Senolytics and senostatics as adjuvant tumour therapy
por: Short, Susan, et al.
Publicado: (2019)

Senolytic drugs: from discovery to translation
por: Kirkland, J. L., et al.
Publicado: (2020)

Cardiac glycosides are broad-spectrum senolytics
por: Guerrero, Ana, et al.
Publicado: (2019)

SENOLYTIC DRUGS: DISCOVERY, TRANSLATION, AND APPLICATION
por: LeBrasseur, Nathan
Publicado: (2019)

Galactose‐modified duocarmycin prodrugs as senolytics
por: Guerrero, Ana, et al.
Publicado: (2020)

NAD(+), Senolytics, or Pyruvate for Healthy Aging?
por: Zhou, Fang-Qiang
Publicado: (2021)

Therapeutic Potential of Senolytics in Cardiovascular Disease
por: Dookun, Emily, et al.
Publicado: (2020)

Discovery of senolytics using machine learning
por: Smer-Barreto, Vanessa, et al.
Publicado: (2023)

Moving senolytics closer to the clinic in IPF
por: Kramer, Daniel, et al.
Publicado: (2023)

Increased cellular senescence in doxorubicin-induced murine ovarian injury: effect of senolytics
por: Gao, Yueyue, et al.
Publicado: (2023)

Development of a BCL-xL and BCL-2 dual degrader with improved anti-leukemic activity,
por: Lv, Dongwen, et al.
Publicado: (2021)

Senolytic CAR T cells reverse senescence-associated pathologies
por: Amor, Corina, et al.
Publicado: (2020)

Senolytics: Eliminating Senescent Cells and Alleviating Intervertebral Disc Degeneration
por: Wu, Yuhao, et al.
Publicado: (2022)

Can molecular targeting the TNFα-ERK-ETS1-IL27Rα pathway keep us young and healthy by protecting HSCs from aging?
por: He, Yonghan, et al.
Publicado: (2020)

Senolytic treatment reduces oxidative protein stress in an aging male murine model of post‐traumatic osteoarthritis
por: Chin, Alexander F., et al.
Publicado: (2023)

Depletion of senescent-like neuronal cells alleviates cisplatin-induced peripheral neuropathy in mice
por: Acklin, Scarlett, et al.
Publicado: (2020)

Senolytic therapy to modulate the progression of Alzheimer’s Disease (SToMP-AD) – Outcomes from the first clinical trial of senolytic therapy for Alzheimer’s disease
por: Gonzales, Mitzi M., et al.
Publicado: (2023)

Identification and characterization of Cardiac Glycosides as senolytic compounds
por: Triana-Martínez, Francisco, et al.
Publicado: (2019)

Senolytics: A Novel Strategy for Neuroprotection in ALS?
por: Maximova, Alexandra, et al.
Publicado: (2021)

Senolytic Therapy for Cerebral Ischemia-Reperfusion Injury
por: Lim, Songhyun, et al.
Publicado: (2021)

Anti-aging: senolytics or gerostatics (unconventional view)
por: Blagosklonny, Mikhail V.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_85nvepbel8cr6vf7rdsqga7p9u